Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

AMLX

Rangering i aksjer #4341
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aksjekurs
$28.83
Sist synkronisert: 2026-10-20
Markedsverdi
$3.62B
Endring (1 dag)
5.49%
Endring (1 år)
88.56%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)

Kategori

Healthcare
Historikk for aksjesplitt for Amylyx Pharmaceuticals, Inc. (AMLX)
Aksjen Amylyx Pharmaceuticals, Inc. (symbol: AMLX) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én AMLX-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 AMLX-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL